Other safety alerts
|
| |
| Australia: Counterfeit Rybelsus Semaglutide tablets detected |
| |
The Therapeutic Goods Administration (TGA) announces that consumers and health professionals should be aware that examples of counterfeit Rybelsus-labelled products have been stopped at the Australian border. These tablets may pose a serious risk to their health and should not be used. While these products appear to be genuine, the manufacturer Novo Nordisk has confirmed that the batch number on these counterfeit Rybelsus 7mg products - PS6LA8S - is not genuine.
Consumers are advised that these counterfeit Rybelsus tablets have not been assessed by the TGA for quality, safety or efficacy as required under Australian legislation for therapeutic goods. Consumers should be warned that manufacturers of counterfeit goods are producing products that, to the untrained eye, may appear legitimate, highlighting the need to purchase your medicines from legitimate sources. The TGA advises consumers to exercise extreme caution when purchasing medicines from unknown overseas websites.
Please refer to the following website in TGA for details:
http://www.tga.gov.au/news/safety-alerts/counterfeit-rybelsus-semaglutide-tablets-detected
In Hong Kong, Rybelsus Tablets 7mg (HK-67432) is a pharmaceutical product registered by Novo Nordisk Hong Kong Ltd. The product is a prescription-only medicine. The pack of the counterfeit Rybelsus product mentioned in the above TGA’s announcement is different from the registered pack of the product in Hong Kong.
Ends/Thursday, Jun 26, 2025
Issued at HKT 17:30
|
| |
